Abstract：
Microscopic colitis (MC) is associated with several risk factors; however, their relative risk has been variable and not thoroughly evaluated. We aimed to quantify the risk of medical comorbidities and medications associated with MC and treatment offered to these patients.
A population-based retrospective analysis in International Business Machines (IBM) Explorys (1999-2018), a pooled, de-identified database of 63 million patients in the USA, was performed. Odds ratios (OR) were calculated between MC and other diseases/medications. MC patients were also stratified by age to assess trends of MC in different age groups.
A total of 1130 patients had MC in the database. Among medications, non-steroidal anti-inflammatory agents (OR, 20.2) and proton pump inhibitors (OR, 12.1) were associated with highest odds of MC. Among medical comorbidities, infectious gastroenteritis (OR, 26.6) and celiac disease (OR, 22.5) had the highest odds of being associated with MC. Tobacco smoking, psoriasis, Sjogren\'s syndrome, Clostridium difficile infection, and malabsorption syndromes all conferred odds greater than 10.
Early identification of MC is critical for minimizing morbidity and mortality. Epidemiologic information can be integrated with current clinical algorithms to more rapidly identify patients at risk.
A population-based retrospective analysis in International Business Machines (IBM) Explorys (1999-2018), a pooled, de-identified database of 63 million patients in the USA, was performed. Odds ratios (OR) were calculated between MC and other diseases/medications. MC patients were also stratified by age to assess trends of MC in different age groups.
A total of 1130 patients had MC in the database. Among medications, non-steroidal anti-inflammatory agents (OR, 20.2) and proton pump inhibitors (OR, 12.1) were associated with highest odds of MC. Among medical comorbidities, infectious gastroenteritis (OR, 26.6) and celiac disease (OR, 22.5) had the highest odds of being associated with MC. Tobacco smoking, psoriasis, Sjogren\'s syndrome, Clostridium difficile infection, and malabsorption syndromes all conferred odds greater than 10.
Early identification of MC is critical for minimizing morbidity and mortality. Epidemiologic information can be integrated with current clinical algorithms to more rapidly identify patients at risk.
摘要：
显微镜结肠炎（MC）与几个危险因素有关；然而，他们的相对风险是可变的，没有彻底评估。我们旨在量化与MC相关的医疗合并症和药物以及为这些患者提供的治疗的风险。
国际商业机器（IBM）探索（1999-2018），基于人群的回顾性分析，一个集合，美国6300万患者的去识别数据库，已执行。计算MC和其他疾病/药物之间的赔率比(OR)。还按年龄对MC患者进行了分层，以评估不同年龄组的MC趋势。
数据库中共有1130名患者出现MC。在药物中，非甾体抗炎药（OR，20.2)和质子泵抑制剂(OR，12.1）与MC的最高几率相关。在医疗合并症中，传染性胃肠炎（或，26.6)和乳糜泻(OR，22.5）与MC相关的可能性最高。吸烟,牛皮癣,干燥综合征,艰难梭菌感染,吸收不良综合征的几率都大于10。
早期识别MC对于降低发病率和死亡率至关重要。流行病学信息可以与当前的临床算法相结合，以更快地识别有风险的患者。
国际商业机器（IBM）探索（1999-2018），基于人群的回顾性分析，一个集合，美国6300万患者的去识别数据库，已执行。计算MC和其他疾病/药物之间的赔率比(OR)。还按年龄对MC患者进行了分层，以评估不同年龄组的MC趋势。
数据库中共有1130名患者出现MC。在药物中，非甾体抗炎药（OR，20.2)和质子泵抑制剂(OR，12.1）与MC的最高几率相关。在医疗合并症中，传染性胃肠炎（或，26.6)和乳糜泻(OR，22.5）与MC相关的可能性最高。吸烟,牛皮癣,干燥综合征,艰难梭菌感染,吸收不良综合征的几率都大于10。
早期识别MC对于降低发病率和死亡率至关重要。流行病学信息可以与当前的临床算法相结合，以更快地识别有风险的患者。
